文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTATATE PET/CT后大部分预期管理变更得以实施

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.
PubMed 文献 · J Nucl Med · 2017-05-04

这项前瞻性转诊医师调查研究纳入130例神经内分泌肿瘤患者,评估68Ga-DOTATATE PET/CT对管理决策的临床影响。96例完成全部问卷,48例(50%)报告预期管理变更,其中36例(75%)最终实施;电子病历核查确认所有可查病历(36/96;38%)的Q3应答。

要点

  • 68Ga-DOTATATE PET/CT在48/96例(50%)中引起预期管理变更。
  • 48例预期变更中36例(75%)最终实施。
  • Q3应答在全部有电子病历的患者(36/96;38%)中得到确认。

核心结论

  • 该前瞻性研究证实68Ga-DOTATATE PET/CT对神经内分泌肿瘤患者的预期管理有显著影响(50%发生变更),并显著证明了这些预期管理变更具有高实施率(75%)。

研究设计与样本

  • 前瞻性转诊医师问卷调查,纳入130例因初始或后续管理决策而转诊行68Ga-DOTATATE PET/CT的神经内分泌肿瘤患者(NCT02174679)。
  • 转诊医师在扫描前完成问卷Q1以表明无PET/CT信息时的治疗计划,阅片后立即完成Q2以表示预期管理变更,6个月后完成Q3以核实预期变更是否实际实施。
  • 为进一步验证Q3应答,进行了系统性电子病历回顾。

主要发现

  • 130例患者中96例(74%)的转诊医师完成了全部3份问卷。
  • 68Ga-DOTATATE PET/CT在48/96例(50%)中引起预期管理变更(Q2)。
  • 这些变更最终在36/48例(75%)中得以实施(Q3)。
  • Q3应答在全部有电子病历的患者中得到确认(36/96;38%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this prospective referring-physician-based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Calais J, Czernin J, Eiber M, et al. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017. PMID: 28473600. doi:10.2967/jnumed.117.192450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。